Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Google 2009 PageRank: #2 Among Top Health News and Media Publications
Google 2009 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2009 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2009 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
2009 SEP 28 ... Cancer Center. Druker and Lydon's research led to the development of imatinib (or Gleevec). Sawyers' research spearheaded efforts toward combating the resistance to...
2009 AUG 10 ... drug-resistant cases of CML and Ph+ ALL. First-generation therapies, such as imatinib (Gleevec®), and second-generation therapies, such as dasatinib (Sprycel®) and nilotinib ...
2009 NOV 16 ... specific mutations that confer clinical resistance to marketed CML therapies imatinib (Gleevec®), dasatinib (Sprycel®), and nilotinib (Tasigna®). "We ...
2009 NOV 2 ... have identified a drug that is currently approved to treat certain types of cancer, Gleevec, that could provide the first treatment for scleroderma, a chronic connective tissue ...
2009 AUG 10 ... of two chromosomes. Her discovery was a key step in the eventual discovery of Gleevec, a targeted therapy for CML patients. Rowley, 84, is the Blum-Riese ...
2009 AUG 17 ... by multiple schwannomas, underlying the need for biological targeted therapies. Gleevec (STI571, imatinib mesylate), in addition to the bcr-abl oncogene in chronic myelogenous ...
2009 OCT 19 ... in the appropriate use of expensive medications." Known commercially as Gleevec®, imatinib is a pill that's used to treat some adult leukemias and ...
2009 NOV 2 ... endpoint in the first head-to-head comparison with the company's groundbreaking drug Gleevec® (imatinib mesylate) tablets*. Tasigna produced faster and deeper responses than ...
2009 NOV 2 ... endpoint in the first head-to-head comparison with the company's groundbreaking drug Gleevec=AE (imatinib mesylate) tablets*. Tasigna produced faster and deeper responses than...
2009 OCT 19 ... kinase inhibitor dasatinib (Sprycel; BMS-354825) is approved for use in imatinib (Gleevec; STI 571)resistant or-intolerant chronic myelogenous leukemia and may be useful for ...
2009 AUG 31 ... (IHC) in part prompted the initiation of a phase 2 clinical trial of imatinib mesylate (Gleevec, Novartis Pharmaceuticals, East Hanover, NJ) for the treatment of advanced MCC," ...
2009 NOV 23 ... leads to the fusion-protein BCR-ABL. Prior to the development of imatinib mesylate (Gleevec), treatment was limited and provided only limited survival benefit," researchers in the ...
2009 SEP 21 ... the pharmacokinetics of imatinib,' new data in pharmacokinetics. "Imatinib mesylate (Gleevec/Glivec), which has revolutionized the treatment of chronic myeloid leukemias (CML) and ...
2009 NOV 16 ... of the clusters could be completely blocked by adding a c-kit/tyrosine kinase inhibitor, Gleevec (imatinib mesylate; Novartis International, Basel, Switzerland, ...
2009 AUG 24 ... CD33+ CML cells when treatment was combined with the Bcr-Abl tyrosine kinase inhibitor, Gleevec. Importantly, ex vivo treatment of patient-derived CD33+ AML tumor cells with ...
2009 SEP 28 ... A report, 'Tumor lysis syndrome after starting treatment with Gleevec in a patient with chronic myelogenous leukemia,' is newly published data in Journal of ...
2009 OCT 19 ... associated with chronic fibrosing diseases and may potentially be treated with imatinib (Gleevec), a c-KIT blocker," scientists in the United States report. ...
2009 NOV 9 ... for AML but are expected to have minimal impact on patient outcomes. Gleevec (imatinib; Novartis) is the only molecular targeted therapy used extensively in the ...
2009 AUG 3 ... "This study will determine whether MTT assays accurately assess the effect of STI571 (Gleevec; Abl kinase inhibitor) on the viability of cancer cells containing highly active Abl ...
2009 NOV 9 ... diagnosed patients with chronic myeloid leukemia (CML). The Rationale and Insight for Gleevec High-Dose Therapy (RIGHT) trial is a multicenter study of imatinib 400 mg twice a day as ...
